Literature DB >> 31431352

Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.

Jacopo Giuliani1, Andrea Bonetti2.   

Abstract

Entities:  

Keywords:  Cost of drugs; Nivolumab; Pembrolizumab; Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC); Second-line

Mesh：

Substances：

Year:  2019        PMID： 31431352     DOI： 10.1016/j.oraloncology.2019.08.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN： 1368-8375            Impact factor:   5.337


× No keyword cloud information.
  3 in total

1.  Peripheral Blood Markers Associated with Immune-Related Adverse Effects in Patients Who Had Advanced Non-Small Cell Lung Cancer Treated with PD-1 Inhibitors.

Authors:  Wenhui Liu; Yiping Liu; Fang Ma; Bao Sun; Ying Wang; Jianquan Luo; Mouze Liu; Zhiying Luo
Journal:  Cancer Manag Res       Date:  2021-01-27       Impact factor: 3.989

2.  Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer.

Authors:  Jacopo Giuliani; Andrea Bonetti
Journal:  Cancer Drug Resist       Date:  2021-04-27

Review 3.  Significant function and research progress of biomarkers in gastric cancer.

Authors:  Dong Mei Ye; Gaosheng Xu; Wei Ma; Yuxuan Li; Weiru Luo; Yiyang Xiao; Yong Liu; Zhiwei Zhang
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.